Potential antiviral therapies for coronavirus disease 2019 (COVID-19)
The novel coronavirus disease (COVID-2019) caused by severe acute respiratory syndrome coronavirus (called SARS-CoV-2) emerged in China in December 2019 and then spread rapidly to more than 200 countries around the world, including the United States, Spain, Italy, the United Kingdom, Germany, France...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989131/ http://dx.doi.org/10.1016/B978-0-323-90769-9.00036-0 |
_version_ | 1784683099839266816 |
---|---|
author | Singh, Jasdeep Singhal, Divya |
author_facet | Singh, Jasdeep Singhal, Divya |
author_sort | Singh, Jasdeep |
collection | PubMed |
description | The novel coronavirus disease (COVID-2019) caused by severe acute respiratory syndrome coronavirus (called SARS-CoV-2) emerged in China in December 2019 and then spread rapidly to more than 200 countries around the world, including the United States, Spain, Italy, the United Kingdom, Germany, France, Japan, and South Korea, resulting in more than 208,112 deaths worldwide. As there is no approved vaccine or therapeutic available to control the COVID-2019 pandemic, scientists across the world are trying every possible way to find antivirals specific to this virus. In this urgent situation, parallel to the development of new vaccines and drugs, many previously approved antiviral drugs of broad range such as arbidol, interferon alfa, chloroquine, remdesivir, and favipiravir are presently undergoing clinical trials against COVID-19. So far some positive findings have been obtained, and here we present a thorough overview of all possible antiviral medicines that can control this pandemic of SARS-CoV-2. |
format | Online Article Text |
id | pubmed-8989131 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
record_format | MEDLINE/PubMed |
spelling | pubmed-89891312022-04-11 Potential antiviral therapies for coronavirus disease 2019 (COVID-19) Singh, Jasdeep Singhal, Divya Data Science for COVID-19 Article The novel coronavirus disease (COVID-2019) caused by severe acute respiratory syndrome coronavirus (called SARS-CoV-2) emerged in China in December 2019 and then spread rapidly to more than 200 countries around the world, including the United States, Spain, Italy, the United Kingdom, Germany, France, Japan, and South Korea, resulting in more than 208,112 deaths worldwide. As there is no approved vaccine or therapeutic available to control the COVID-2019 pandemic, scientists across the world are trying every possible way to find antivirals specific to this virus. In this urgent situation, parallel to the development of new vaccines and drugs, many previously approved antiviral drugs of broad range such as arbidol, interferon alfa, chloroquine, remdesivir, and favipiravir are presently undergoing clinical trials against COVID-19. So far some positive findings have been obtained, and here we present a thorough overview of all possible antiviral medicines that can control this pandemic of SARS-CoV-2. 2022 2022-01-14 /pmc/articles/PMC8989131/ http://dx.doi.org/10.1016/B978-0-323-90769-9.00036-0 Text en Copyright © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Singh, Jasdeep Singhal, Divya Potential antiviral therapies for coronavirus disease 2019 (COVID-19) |
title | Potential antiviral therapies for coronavirus disease 2019 (COVID-19) |
title_full | Potential antiviral therapies for coronavirus disease 2019 (COVID-19) |
title_fullStr | Potential antiviral therapies for coronavirus disease 2019 (COVID-19) |
title_full_unstemmed | Potential antiviral therapies for coronavirus disease 2019 (COVID-19) |
title_short | Potential antiviral therapies for coronavirus disease 2019 (COVID-19) |
title_sort | potential antiviral therapies for coronavirus disease 2019 (covid-19) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989131/ http://dx.doi.org/10.1016/B978-0-323-90769-9.00036-0 |
work_keys_str_mv | AT singhjasdeep potentialantiviraltherapiesforcoronavirusdisease2019covid19 AT singhaldivya potentialantiviraltherapiesforcoronavirusdisease2019covid19 |